Phaseline

Companies › J-Pharma

J-Pharma: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology, Other; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Nanvuranlat–Phase 3Advanced Biliary Tract CancerOct 2027
JPH034–Phase 1Health Adult Subjects–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07534657JPH034Phase 1Health Adult SubjectsOtherOct 2026
NCT07265674NanvuranlatPhase 3Advanced Biliary Tract CancerOncologyOct 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Relay Therapeutics Haihe Biopharma Onconic Therapeutics Monte Rosa Therapeutics Beijing Tide Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.